Thyroid hormone as a therapeutic option for treating ischaemic heart disease: From early reperfusion to late remodelling

被引：26

作者：

Pantos, Constantinos ^{[1
]}

Mourouzis, Iordanis ^{[1
]}

Cokkinos, Dennis V. ^{[2
,3
]}

机构：

[1] Univ Athens, Sch Med, Dept Pharmacol, GR-11527 Athens, Greece

[2] Onassis Cardiac Surg Ctr, Cardiol Dept 1, Athens, Greece

[3] Acad Athens, Biomed Res Fdn, Athens, Greece

来源：

VASCULAR PHARMACOLOGY | 2010年 / 52卷 / 3-4期

关键词：

Thyroid hormone; Myocardial ischaemia; Postischaemic cardiac remodelling; ACUTE MYOCARDIAL-INFARCTION; IMPROVES CARDIAC-FUNCTION; LEFT-VENTRICULAR FUNCTION; 3,5-DIIODOTHYROPROPIONIC ACID; CONTRACTILE DYSFUNCTION; POSTISCHEMIC RECOVERY; EXTRACELLULAR-MATRIX; REPLACEMENT THERAPY; GENE-EXPRESSION; MESSENGER-RNA;

D O I：

10.1016/j.vph.2009.11.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Thyroid hormone (TH), apart from its "classical" actions on cardiac contractility and heart rhythm. appears to regulate various intracellular signalling pathways related to response to Stress and cardiac remodelling. There is now accumulating experimental and clinical evidence showing a beneficial effect of TH on limiting myocardial ischaemic injury, preventing/reversing Post infarction cardiac remodelling and improving cardiac hemodynamics. Thyroid analogs have already been developed and may allow TH use in clinical practice. However, the efficacy of TH in the treatment of cardiac diseases is now awaiting to be tested in large clinical trials. (C) 2009 Elsevier Inc. All rights reserved.

引用

页码：157 / 165

页数：9